Prame and ctcfl-reactive tcrs for the treatment of ovarian cancer

HIGHLIGHTS

• who: Rosa A. van Amerongen et al. from the Johannes Gutenberg University Mainz, Germany have published the paper: PRAME and CTCFL-reactive TCRs for the treatment of ovarian cancer, in the Journal: (JOURNAL)
• what: The authors aimed to identify strictly tumor-specific TAAs in ovarian cancer by only selecting DE genes with a FC u2265 20 compared to all healthy tissues of risk. In the study , thus far only T_cells reactive against CLDN6 peptide-loaded cells, but not against CLDN6 transduced cells were identified.
• how: In vivo killing potential of the PRAME TCRs . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.